Table 2.
Features of participants to the different studies: all included subjects, all vaccine recipients, placebo recipients, and single vaccine recipients
| N. of studies | N. of participants | Median female percentage; 25th-75th percentile (N. of studies) |
Median age; 25th-75th percentile (N. of studies) |
Median percentage of subjects with chronic conditions; 25th-75th percentile (N. of studies) |
Median headache rank position among side effects; 25th-75th percentile (N. of studies) |
|
|---|---|---|---|---|---|---|
| All included subjects | 84 | 1,568,199 |
58.4%; 49.4–69.5% (N = 76) |
39.8; 35.5–49.9 (N = 62) |
37.2%; 18.2–92.5% (N = 19) |
3rd; 3rd-4th (N = 57) |
| All Vaccines recipients | 84 | 1,522,830 |
59.4%; 49.1–71.1% (N = 72) |
41.0; 35.3–48.6 (N = 56) |
34.7%; 16.9–96.3% (N = 22) |
3rd; 3rd-4th (N = 56) |
| BNT162b2 | 41 | 1,047,545 |
64.3%; 52.3–71.7% (N = 34) |
43.5; 38.2–57.3 (N = 26) |
85.0%; 39.4–100% (N = 9) |
3rd; 3rd-4th (N = 32) |
| ChAdOx1 | 19 | 388,147 |
71.2%; 61.1–76.3% (N = 12) |
37.5; 35.8–49.7 (N = 8) |
45.8%; 41.5–50.1% (N = 2) |
4th; 3rd-4th (N = 12) |
| PiCoVacc | 9 | 15,177 |
62.4%; 49.0%-67.7% (N = 6) |
35.8; 35.4–36.1 (N = 5) |
15.8%; 15.2–16.3% (N = 2) |
3rd; 2nd-3rd (N = 7) |
| mRNA-1273 | 5 | 16,575 |
51.8%; 41.1–64.4% (N = 4) |
64.7; 48.9–66.7 (N = 3) |
100%; n.a (N = 1) |
3rd; 2nd-3rd (N = 3) |
| NVX-CoV2373 | 3 | 7,612 |
48.8%; 48.7–49.0% (N = 2) |
56.0; n.a (N = 1) |
n.r |
3rd; 2nd-3rd (N = 2) |
| Placebo Recipients | 21 | 45,760 |
52.4%; 47.6–54.2% (N = 20) |
43.3; 37.6–48.1 (N = 19) |
13.8%; 4.8–26.9% (N = 5) |
3rd; 2nd-4th (N = 18) |
Vaccines reported by less than three studies were not included in the table
N.R. not reported, N.A. not available